Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia – systematic review and meta-analysis of randomised controlled trials
- 9 August 2012
- journal article
- research article
- Published by Informa UK Limited in Acta Oncologica
- Vol. 52 (1), 18-29
- https://doi.org/10.3109/0284186x.2012.702921
Abstract
Background: Current guidelines are inconclusive regarding intravenous (IV) iron for treatment of chemotherapy-induced anaemia (CIA). Material and methods: Systematic review and meta-analysis of randomised controlled trials comparing IV iron with no iron or oral iron for treatment of chemotherapy induced anaemia (CIA). Primary outcomes: haematopoietic response and red blood cell (RBC) transfusion requirements. For dichotomous data, relative risks (RR) with 95% confidence intervals (CIs) were estimated and pooled. For continuous data, weighted mean differences were calculated. Results: Eleven trials included 1681 patients, the majority examining the addition of IV iron to erythropoiesis stimulating agents (ESA) (1562 patients, 92.9%). IV iron significantly increased haematopoietic response rate [RR 1.28 (95% CI 1.125–1.45), seven trials with ESA] and decreased the rate of blood transfusions both in trials with ESA [RR 0.76 (95% CI 0.61–0.95), seven trials] and without ESA [RR 0.52 (95% CI 0.34–0.80)]. The increase in haematopoietic response rate correlated with total IV iron dose, regardless of baseline iron status. Mortality and safety profile was comparable between groups. Conclusions: IV iron added to ESA results in an increase in haematopoietic response and reduction in the need for RBC transfusions, with no difference in mortality or adverse events.Keywords
This publication has 33 references indexed in Scilit:
- Erythropoiesis-stimulating agents in cancer patients: reflections on safetyExpert Review of Clinical Pharmacology, 2011
- American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With CancerJournal of Clinical Oncology, 2010
- Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for useAnnals Of Oncology, 2010
- The role of iron supplementation during epoietin treatment for cancer-related anemiaMedical Oncology, 2008
- Erythropoietin and iron-restricted erythropoiesisExperimental Hematology, 2007
- EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 updateEuropean Journal Of Cancer, 2007
- Cancer-related anemia and recombinant human erythropoietin—an updated overviewNature Clinical Practice Oncology, 2006
- Recombinant Human Erythropoietin and Overall Survival in Cancer Patients: Results of a Comprehensive Meta-analysisJNCI Journal of the National Cancer Institute, 2005
- Anemia of Chronic DiseaseNew England Journal of Medicine, 2005
- The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patientsEuropean Journal Of Cancer, 2004